<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	
	xmlns:georss="http://www.georss.org/georss"
	xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#"
	>

<channel>
	<title>heart failure &#8211; The American Journal of Medicine Blog</title>
	<atom:link href="https://amjmed.org/category/cardiology/heart-failure/feed/" rel="self" type="application/rss+xml" />
	<link>https://amjmed.org</link>
	<description>&#039;The Green Journal&#039;</description>
	<lastBuildDate>Tue, 25 Apr 2023 23:24:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://i0.wp.com/amjmed.org/wp-content/uploads/2018/11/cropped-ajmcover_2013-square-web.jpg?fit=32%2C32&#038;ssl=1</url>
	<title>heart failure &#8211; The American Journal of Medicine Blog</title>
	<link>https://amjmed.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">56439181</site>	<item>
		<title>Regional Adiposity Distribution and Incident Heart Failure</title>
		<link>https://amjmed.org/regional-adiposity-distribution-and-incident-heart-failure/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Mon, 13 Mar 2023 15:18:44 +0000</pubDate>
				<category><![CDATA[American Journal of Medicine]]></category>
		<category><![CDATA[Clinical Research]]></category>
		<category><![CDATA[Diabetes/Obesity]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[obesity]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=7337</guid>

					<description><![CDATA[&#8220;Relationship Between Regional Adiposity Distribution and Incident Heart Failure in General Population without Cardiovascular Disease&#8221; was originally published in the March 2023 issue of The American Journal of Medicine. Abstract Background Obesity is associated with a high risk of heart failure. However, the contribution of regional fat distribution evaluated using bioimpedance analysis toward heart failure [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">7337</post-id>	</item>
		<item>
		<title>High Poverty Predicts High Rates of Hypertension, Diabetes &#038; Hospital Readmissions (video)</title>
		<link>https://amjmed.org/high-poverty-predicts-high-rates-of-hypertension-diabetes-hospital-readmissions-video/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Wed, 07 Sep 2022 17:25:19 +0000</pubDate>
				<category><![CDATA[Alpert's videos]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Diabetes/Obesity]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[hypertension]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[Hypertension]]></category>
		<category><![CDATA[poverty]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=7187</guid>

					<description><![CDATA[People often say that your ZipCode is your destiny. This assertion is borne out yet again in &#8220;Influence of Neighborhood Conditions on Recurrent Hospital Readmissions in Patients with Heart Failure: A Cohort Study&#8221; by Shootman et al. In this video, Joseph S. Alpert, MD, editor-in-chief of the American Journal of Medicine, talks about the affect [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">7187</post-id>	</item>
		<item>
		<title>Digoxin &#038; Outcomes in Patients with Heart Failure &#038; AF (video)</title>
		<link>https://amjmed.org/digoxin-outcomes-in-patients-with-heart-failure-af-video/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Sat, 05 Dec 2020 23:29:51 +0000</pubDate>
				<category><![CDATA[Alpert's videos]]></category>
		<category><![CDATA[American Journal of Medicine]]></category>
		<category><![CDATA[Atrial Fibrillation]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Clinical Research]]></category>
		<category><![CDATA[Drugs]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[atrial fibrillation]]></category>
		<category><![CDATA[digoxin]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6705</guid>

					<description><![CDATA[What is the benefit of digoxin initiation in hospitalized patients with heart failure with reduced ejection fraction and heart failure with preserved ejection fraction and atrial fibrillation? In this video, Dr. Joseph S. Alpert, AJM editor-in-chief, explains the new research findings in &#8220;Digoxin Initiation and Outcomes in Patients with Heart Failure (HFrEF and HFpEF) and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6705</post-id>	</item>
		<item>
		<title>Digoxin in Heart Failure Patients with Preserved Ejection Fraction (video)</title>
		<link>https://amjmed.org/digoxin-in-heart-failure-patients-with-preservedejection-fraction-video/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Thu, 05 Nov 2020 22:02:49 +0000</pubDate>
				<category><![CDATA[Alpert's videos]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Clinical Research]]></category>
		<category><![CDATA[Drugs]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[digoxin]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6604</guid>

					<description><![CDATA[Digoxin reduces the risk of heart failure hospitalization in heart failure patients with reduced ejection fraction; this study looks at the efficacy of digoxin in patients with preserved ejection fraction. In this video, AJM Editor-in-Chief Dr. Joseph S. Alpert explains &#8220;Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction,&#8221; which appears [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6604</post-id>	</item>
		<item>
		<title>Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure (video)</title>
		<link>https://amjmed.org/safety-of-outpatient-milrinone-infusion-in-end-stage-heart-failure-video/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Fri, 10 Jul 2020 21:29:34 +0000</pubDate>
				<category><![CDATA[Alpert's videos]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Clinical Research]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Milrinone Infusion]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6594</guid>

					<description><![CDATA[Milrinone infusion is one of the few &#8220;non-device&#8221; therapies for patients with New York Heart Association class IV, stage D heart failure, but it has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation. Is it beneficial overall? In this video, AJM Editor-in-Chief Joseph S. Alpert, MD, discusses new research on the safety [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6594</post-id>	</item>
		<item>
		<title>Growing Mismatch Between Evidence Generation and Implementation in Heart Failure</title>
		<link>https://amjmed.org/growing-mismatch-between-evidence-generation-and-implementation-in-heart-failure/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Mon, 11 May 2020 13:43:02 +0000</pubDate>
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[cardiology]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6475</guid>

					<description><![CDATA[Heart failure is a leading cause of morbidity and mortality globally. The natural history of heart failure with reduced ejection fraction (HFrEF) has been altered with the development of multiple therapeutic agents targeting maladaptive biologic pathways, including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists. Although mechanistic studies overlapped, the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6475</post-id>	</item>
		<item>
		<title>Strategies of Unloading the Failing Heart from Metabolic Stress</title>
		<link>https://amjmed.org/strategies-of-unloading-the-failing-heart-from-metabolic-stress/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Thu, 05 Mar 2020 13:23:41 +0000</pubDate>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[stress]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6429</guid>

					<description><![CDATA[&#160; We propose a unifying perspective of heart failure in patients with type 2 diabetes mellitus. The reasoning is as follows: cellular responses to fuel overload include dysregulated insulin signaling, impaired mitochondrial respiration, reactive oxygen species formation, and the accumulation of certain metabolites, collectively termed glucolipotoxicity. As a consequence, cardiac function is impaired, with intracellular [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6429</post-id>	</item>
		<item>
		<title>The Impact of Substance Abuse on Heart Failure Hospitalizations</title>
		<link>https://amjmed.org/the-impact-of-substance-abuse-on-heart-failure-hospitalizations/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Sat, 15 Feb 2020 13:53:50 +0000</pubDate>
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Drugs]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Hospitalization]]></category>
		<category><![CDATA[Drug Abuse]]></category>
		<category><![CDATA[Featured]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6410</guid>

					<description><![CDATA[The burden of substance abuse among patients with heart failure and its association with subsequent emergency department visits and hospital admissions are poorly characterized. Methods We evaluated the medical records of patients with a diagnosis of heart failure treated at the University of California–San Diego from 2005 to 2016. We identified substance abuse via diagnosis [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6410</post-id>	</item>
		<item>
		<title>Substance Abuse &#038; Hospitalization for Heart Failure (video)</title>
		<link>https://amjmed.org/substance-abuse-hospitalization-for-heart-failure-video/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Mon, 10 Feb 2020 16:51:47 +0000</pubDate>
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Clinical Research]]></category>
		<category><![CDATA[Drugs]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[cocaine]]></category>
		<category><![CDATA[Drug Abuse]]></category>
		<category><![CDATA[meth]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6238</guid>

					<description><![CDATA[Substance abuse is obviously not a health lifestyle choice, but if you have heart failure and take street drugs like meth or cocaine, the combination can be deadly. In this video clip, American Journal of Medicine Editor-in-Chief Dr. Joseph S. Alpert urges physicians to warn heart failure patients against street use drugs. You can read [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6238</post-id>	</item>
		<item>
		<title>Salt, No Salt, or Less Salt for Patients With Heart Failure?</title>
		<link>https://amjmed.org/salt-no-salt-or-less-salt-for-patients-with-heart-failure/</link>
		
		<dc:creator><![CDATA[Managing Editor]]></dc:creator>
		<pubDate>Thu, 09 Jan 2020 13:55:24 +0000</pubDate>
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Nutrition]]></category>
		<category><![CDATA[salt]]></category>
		<category><![CDATA[cardiology]]></category>
		<category><![CDATA[Diet]]></category>
		<category><![CDATA[Featured]]></category>
		<guid isPermaLink="false">https://amjmed.org/?p=6377</guid>

					<description><![CDATA[&#160; Restricting dietary sodium is a common recommendation given by clinicians to patients with heart failure and is one supported by current guidelines. However, the quality of evidence for this recommendation is suboptimal, and there is no consensus on the optimal level of sodium intake. Though excessive sodium intake is associated with left ventricular hypertrophy [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">6377</post-id>	</item>
	</channel>
</rss>